Your browser doesn't support javascript.
loading
Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.
Schnute, Mark E; Benoit, Stephen E; Buchler, Ingrid P; Caspers, Nicole; Grapperhaus, Margaret L; Han, Seungil; Hotchandani, Rajeev; Huang, Nelson; Hughes, Robert O; Juba, Brian M; Kim, Kyung-Hee; Liu, Erica; McCarthy, Erin; Messing, Dean; Miyashiro, Joy S; Mohan, Shashi; O'Connell, Thomas N; Ohren, Jeffrey F; Parikh, Mihir D; Schmidt, Michelle; Selness, Shaun R; Springer, John R; Thanabal, Venkataraman; Trujillo, John I; Walker, Daniel P; Wan, Zhao-Kui; Withka, Jane M; Wittwer, Arthur J; Wood, Nancy L; Xing, Li; Zapf, Christoph W; Douhan, John.
Afiliação
  • Schnute ME; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Benoit SE; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Buchler IP; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Caspers N; Medicine Design, Pfizer, Groton, Connecticut 06340, United States.
  • Grapperhaus ML; Medicinal Chemistry and Inflammation and Immunology Research, Pfizer, St. Louis, Missouri 63017, United States.
  • Han S; Medicine Design, Pfizer, Groton, Connecticut 06340, United States.
  • Hotchandani R; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Huang N; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Hughes RO; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Juba BM; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Kim KH; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Liu E; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • McCarthy E; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Messing D; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Miyashiro JS; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Mohan S; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • O'Connell TN; Medicine Design, Pfizer, Groton, Connecticut 06340, United States.
  • Ohren JF; Medicine Design, Pfizer, Groton, Connecticut 06340, United States.
  • Parikh MD; Medicine Design, Pfizer, Groton, Connecticut 06340, United States.
  • Schmidt M; Medicinal Chemistry and Inflammation and Immunology Research, Pfizer, St. Louis, Missouri 63017, United States.
  • Selness SR; Medicinal Chemistry and Inflammation and Immunology Research, Pfizer, St. Louis, Missouri 63017, United States.
  • Springer JR; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Thanabal V; Medicine Design, Pfizer, Groton, Connecticut 06340, United States.
  • Trujillo JI; Medicine Design, Pfizer, Groton, Connecticut 06340, United States.
  • Walker DP; Medicinal Chemistry and Inflammation and Immunology Research, Pfizer, St. Louis, Missouri 63017, United States.
  • Wan ZK; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Withka JM; Medicine Design, Pfizer, Groton, Connecticut 06340, United States.
  • Wittwer AJ; Medicinal Chemistry and Inflammation and Immunology Research, Pfizer, St. Louis, Missouri 63017, United States.
  • Wood NL; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Xing L; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Zapf CW; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
  • Douhan J; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
ACS Med Chem Lett ; 10(1): 80-85, 2019 Jan 10.
Article em En | MEDLINE | ID: mdl-30655951
ABSTRACT
Potent covalent inhibitors of Bruton's tyrosine kinase (BTK) based on an aminopyrazole carboxamide scaffold have been identified. Compared to acrylamide-based covalent reactive groups leading to irreversible protein adducts, cyanamide-based reversible-covalent inhibitors provided the highest combined BTK potency and EGFR selectivity. The cyanamide covalent mechanism with BTK was confirmed through enzyme kinetic, NMR, MS, and X-ray crystallographic studies. The lead cyanamide-based inhibitors demonstrated excellent kinome selectivity and rat pharmacokinetic properties.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos